Vaxcyte, Inc.

The company is a clinical-stage biotechnology firm focused on engineering innovative vaccines to protect against severe bacterial diseases. Utilizing its proprietary XpressCF cell-free protein synthesis platform, the enterprise creates broad-spectrum conjugate and novel protein vaccine candidates intended to overcome the manufacturing and immunological constraints of conventional cell-based techniques. Its primary pipeline centers on pneumococcal conjugate vaccines, highlighted by clinical candidates such as VAX-31 and VAX-24, alongside preclinical programs targeting Group A Streptococcus and Shigella infections. Intended recipients and end users encompass pediatric and adult populations susceptible to invasive bacterial illnesses and associated complications.

Operational development and production activities are supported through external manufacturing partnerships and academic collaborations. Commercial fill-finish capacity has been established through a partner facility situated in Greenville, North Carolina, complemented by additional contract manufacturing relationships. The provided text contains no statements regarding corporate headquarters locations, total facility counts, or aggregate employee figures.

Summary of the business section of Vaxcyte's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 507 full-time employees, with most of those based in the United States.”